Monday, September 9, 2013
My son conquered cancer!
I have been silent for a long while. Supporting my son fight cancer over the years has been a nightmare. Now the winter in our lives are over for good. Since 8th May 1997 to Dec 2011 he underwent five major surgeries, chemotherapies , radiations hundred of scans/ MRI /X-rays. today he stands tall reading Law at University of Christchurch.
He received support from CANTEEN New Zealand an organization that supports young people fighting cancer. Today he volunteers at CANTEEN helping other young people living with cancer. This is all possible with God's amazing grace. He is a walking miracle , a great testimony for God and an encouragement for others.
This morning I was so emotional watching my son in Canteen's TV commercial. I can't help but just cried and cried. I like to share this commercial...my son is in this advertisement.
Friday, September 9, 2011
“I am the Lord that healeth thee” (Exodus 15:26).
God’s Word never fails. He will always heal you if you dare to believe Him.
My son who have been fighting bone cancer for 5years is now completely healed. Praise the Lord!
I am been so lost since February last year.This year the cancer came back to the skull and treatment started again this February. I cry out to god in my anguish for an extraordinary miracle.On top of that we are also dealing with trauma from the earthquakes and frequent aftershocks. I thank god, he help us through all our difficulties.
Today he is well , strong and healthy waiting for the doctor to fix a titanuim skull on the left side of his head.
How god heals....it is just awesome.
My son who have been fighting bone cancer for 5years is now completely healed. Praise the Lord!
I am been so lost since February last year.This year the cancer came back to the skull and treatment started again this February. I cry out to god in my anguish for an extraordinary miracle.On top of that we are also dealing with trauma from the earthquakes and frequent aftershocks. I thank god, he help us through all our difficulties.
Today he is well , strong and healthy waiting for the doctor to fix a titanuim skull on the left side of his head.
How god heals....it is just awesome.
Wednesday, February 3, 2010
First Treatment to Improve Survival in 20 Years Now Available for Patients with Osteosarcoma (Bone Cancer)
First Treatment to Improve Survival in 20 Years Now Available for Patients with Osteosarcoma (Bone Cancer)
2010/02/01
Source: asahi.com
Share Article このエントリをはてなブックマークに追加 Yahoo!ブックマークに登録 このエントリをdel.icio.usに登録 このエントリをlivedoorクリップに登録 このエントリをBuzzurlに登録
Osaka, Japan and London, UK, February 1 - Takeda Pharmaceutical Company Limited ("Takeda") and Takeda Pharmaceuticals Europe Limited ("TPEU"), its wholly owned subsidiary for oversight of pan-European sales and marketing, jointly announced today that Mepact(R) (mifamurtide)(1), the first new treatment in 20 years to improve survival in patients with osteosarcoma (malignant bone cancer)(2), is now commercially available in the European Union - via a paid named-patient programme in countries where it is not initially reimbursed.
Osteosarcoma is a rare and often fatal disease, with approximately 1,200 new cases diagnosed in Europe each year; primarily children and young adults(3). The standard treatment for osteosarcoma is surgical removal of the tumour (resection) with combination chemotherapy before and after surgery. Mepact is used in combination with these other anticancer medicines after the cancer has been removed by surgery(1).
Data from the largest independent clinical study ever completed in osteosarcoma (662 patients) conducted by the Children's Oncology Group in the USA, showed that when combined with chemotherapy, Mepact reduced the risk of death by almost one third compared with chemotherapy alone. In addition, 78 percent of patients survived after six years of follow-up after treatment with Mepact and chemotherapy, compared with 70 percent receiving chemotherapy alone(4).
"There has been a significant lack of progress during the last two decades in treating osteosarcoma," said Ian Lewis, Professor of Cancer Studies at St. James University Hospital in Leeds, England. "The availability of mifamurtide brings hope to children and young adults in need of a more positive treatment option for this devastating disease."
Dr Erich Brunn, Chief Executive Officer for TPEU said, "This is an important milestone for Takeda in Europe and for the treatment of osteosarcoma. We are excited to bring this innovation to patients and physicians".
Takeda anticipates that final reimbursement decisions in European countries will be completed during the course of 2010.
About mifamurtide
Mifamurtide works by activating the body's immune system to kill microscopic fragments of tumour cells (micro-metastases) which can break away from the main site of the osteosarcoma in the bone. These fragments can be carried in the blood to other parts of the body, particularly the lungs, allowing the disease to develop further. Disease progression in the lungs is in fact, the primary cause of death in osteosarcoma(5).
Mifamurtide is indicated for the treatment of high-grade, resectable, non-metastatic osteosarcoma after complete surgical removal of the tumour (resection) in children, adolescents and young adults ('High grade' means that the cancer is a severe type, and 'non metastatic' means that it is at an early stage and has not spread. It is administered by intravenous injection over the course of one hour, twice a week for 12 weeks, and then once a week for 24 additional weeks, for a total of 36 weeks of therapy or 48 doses(3).
Safety Information
Clinical experience with mifamurtide suggests that the most common side effects are fever and chills, which can be prevented or reduced with simple premedication such as paracetemol(6). Detailed recommendations for the use of mifamurtide are described in the Summary of Product Characteristics (SPC) which is published in the European Public Assessment Report (EPAR) and is available in all official European Union languages.
Regulatory Progress
In June 2009 Takeda acquired IDM Pharma, Inc., which had already obtained Market Authorization Approval for Mepact in the European Union in March 2009(3), and now, TPEU is responsible for its commercialization in Europe. Millennium: The Takeda Oncology Company (Cambridge, Mass.) is responsible for the global oncology strategy of the Takeda Group and for the development of Mepact.
-ENDS-
(*) A named patient programme is a facility that enables the distribution or supply of a medicine for the treatment of an individual patient, at the specific request of his/her healthcare provider, in cases where the medicine is currently not licensed or reimbursed. Each country has its own regulations that provide a legal and ethical way to allow access to patients who need these particular medicines.
Contacts for the media
Takeda Pharmaceuticals Europe Limited
Nick Francis
Head of Communications
+44...
+44...
nick.francis@tpeu.co.uk
Takeda Pharmaceutical Company Limited
Seizo Masuda
Senior Manager, Corporate Communications
+81...
Masuda_Seizo@takeda.co.jp
References:
(1). Mifamurtide Summary of Product Characteristics 2009.
(2). Grimer RJ, et al. Surgical Outcomes in Osteosarcoma. J Bone Joint Surg [Br] 2002;84-B:395-400.
(3). European Medicines Agency. Assessment Report for MEPACT. Accessed 2 November 2009
(4). Meyers PA, et al. Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival - A Report From The Children’s Oncology Group. J Clin Oncol 2008; 26:633-638.
(5). Meyers PA, Gorlick R: Osteosarcoma. Pediatr Clin North Am 1997; 44:973-989.
(6). Mori K, Ando K, Heymann D. Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases. Expert Rev. Anticancer Ther. 8(2), 151-159 (2008).
About Takeda Pharmaceutical Company Limited
Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. Additional information about Takeda is available through its corporate website www.takeda.com.
About Takeda Pharmaceuticals Europe Limited (TPEU)
Based in London, Takeda Pharmaceuticals Europe leads the overall business activities of Takeda's European subsidiaries ("TES"), providing strategic direction and management support across the region.
2010/02/01
Source: asahi.com
Share Article このエントリをはてなブックマークに追加 Yahoo!ブックマークに登録 このエントリをdel.icio.usに登録 このエントリをlivedoorクリップに登録 このエントリをBuzzurlに登録
Osaka, Japan and London, UK, February 1 - Takeda Pharmaceutical Company Limited ("Takeda") and Takeda Pharmaceuticals Europe Limited ("TPEU"), its wholly owned subsidiary for oversight of pan-European sales and marketing, jointly announced today that Mepact(R) (mifamurtide)(1), the first new treatment in 20 years to improve survival in patients with osteosarcoma (malignant bone cancer)(2), is now commercially available in the European Union - via a paid named-patient programme in countries where it is not initially reimbursed.
Osteosarcoma is a rare and often fatal disease, with approximately 1,200 new cases diagnosed in Europe each year; primarily children and young adults(3). The standard treatment for osteosarcoma is surgical removal of the tumour (resection) with combination chemotherapy before and after surgery. Mepact is used in combination with these other anticancer medicines after the cancer has been removed by surgery(1).
Data from the largest independent clinical study ever completed in osteosarcoma (662 patients) conducted by the Children's Oncology Group in the USA, showed that when combined with chemotherapy, Mepact reduced the risk of death by almost one third compared with chemotherapy alone. In addition, 78 percent of patients survived after six years of follow-up after treatment with Mepact and chemotherapy, compared with 70 percent receiving chemotherapy alone(4).
"There has been a significant lack of progress during the last two decades in treating osteosarcoma," said Ian Lewis, Professor of Cancer Studies at St. James University Hospital in Leeds, England. "The availability of mifamurtide brings hope to children and young adults in need of a more positive treatment option for this devastating disease."
Dr Erich Brunn, Chief Executive Officer for TPEU said, "This is an important milestone for Takeda in Europe and for the treatment of osteosarcoma. We are excited to bring this innovation to patients and physicians".
Takeda anticipates that final reimbursement decisions in European countries will be completed during the course of 2010.
About mifamurtide
Mifamurtide works by activating the body's immune system to kill microscopic fragments of tumour cells (micro-metastases) which can break away from the main site of the osteosarcoma in the bone. These fragments can be carried in the blood to other parts of the body, particularly the lungs, allowing the disease to develop further. Disease progression in the lungs is in fact, the primary cause of death in osteosarcoma(5).
Mifamurtide is indicated for the treatment of high-grade, resectable, non-metastatic osteosarcoma after complete surgical removal of the tumour (resection) in children, adolescents and young adults ('High grade' means that the cancer is a severe type, and 'non metastatic' means that it is at an early stage and has not spread. It is administered by intravenous injection over the course of one hour, twice a week for 12 weeks, and then once a week for 24 additional weeks, for a total of 36 weeks of therapy or 48 doses(3).
Safety Information
Clinical experience with mifamurtide suggests that the most common side effects are fever and chills, which can be prevented or reduced with simple premedication such as paracetemol(6). Detailed recommendations for the use of mifamurtide are described in the Summary of Product Characteristics (SPC) which is published in the European Public Assessment Report (EPAR) and is available in all official European Union languages.
Regulatory Progress
In June 2009 Takeda acquired IDM Pharma, Inc., which had already obtained Market Authorization Approval for Mepact in the European Union in March 2009(3), and now, TPEU is responsible for its commercialization in Europe. Millennium: The Takeda Oncology Company (Cambridge, Mass.) is responsible for the global oncology strategy of the Takeda Group and for the development of Mepact.
-ENDS-
(*) A named patient programme is a facility that enables the distribution or supply of a medicine for the treatment of an individual patient, at the specific request of his/her healthcare provider, in cases where the medicine is currently not licensed or reimbursed. Each country has its own regulations that provide a legal and ethical way to allow access to patients who need these particular medicines.
Contacts for the media
Takeda Pharmaceuticals Europe Limited
Nick Francis
Head of Communications
+44...
+44...
nick.francis@tpeu.co.uk
Takeda Pharmaceutical Company Limited
Seizo Masuda
Senior Manager, Corporate Communications
+81...
Masuda_Seizo@takeda.co.jp
References:
(1). Mifamurtide Summary of Product Characteristics 2009.
(2). Grimer RJ, et al. Surgical Outcomes in Osteosarcoma. J Bone Joint Surg [Br] 2002;84-B:395-400.
(3). European Medicines Agency. Assessment Report for MEPACT. Accessed 2 November 2009
(4). Meyers PA, et al. Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival - A Report From The Children’s Oncology Group. J Clin Oncol 2008; 26:633-638.
(5). Meyers PA, Gorlick R: Osteosarcoma. Pediatr Clin North Am 1997; 44:973-989.
(6). Mori K, Ando K, Heymann D. Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases. Expert Rev. Anticancer Ther. 8(2), 151-159 (2008).
About Takeda Pharmaceutical Company Limited
Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. Additional information about Takeda is available through its corporate website www.takeda.com.
About Takeda Pharmaceuticals Europe Limited (TPEU)
Based in London, Takeda Pharmaceuticals Europe leads the overall business activities of Takeda's European subsidiaries ("TES"), providing strategic direction and management support across the region.
Tuesday, February 17, 2009
Praying for a miracle
I believed in the power of prayers. I am praying for a miracle. My heart bleeds when I have to go through watching my youngest precious son ,Richard going through a biopsy again today. He has been in remission for almost a year and all seems well . He is looking forward to his university studies starting on Monday.However today we were told that lesion on one of his Ribs does not look good and abiopsy was arranged instantly. Results will be on Monday. Please help me pray for this courageous , bright, young 19 year old boy.
Thanks and Hugs to all
Thanks and Hugs to all
Friday, September 19, 2008
Bandanna Challenge in New Zealand
Bandanna Challenge in New Zealand
Staff of CANTEEN is seeking help to sell bandannas in your areas in NZ. This could be in your school or business, or you could volunteer for an hour or two for our street collection or one of our mall stands. If you would like to help us in one of these ways please call the office in your area or 0800CanTeen. We look forward to meeting you!
Friends worlwide can also purchase bandannas online by credit card all year round. Just go to
http://www.canteen.org.nz
CanTeen members are really encouraged when they see people sporting a CanTeen bandanna. Thanks for showing your support for young people in New Zealand living with cancer!
Staff of CANTEEN is seeking help to sell bandannas in your areas in NZ. This could be in your school or business, or you could volunteer for an hour or two for our street collection or one of our mall stands. If you would like to help us in one of these ways please call the office in your area or 0800CanTeen. We look forward to meeting you!
Friends worlwide can also purchase bandannas online by credit card all year round. Just go to
http://www.canteen.org.nz
CanTeen members are really encouraged when they see people sporting a CanTeen bandanna. Thanks for showing your support for young people in New Zealand living with cancer!
Thursday, August 21, 2008
When you were told that your child had bone cancer so " What is Bone Cancer?"
Bone Cancer – Information on Bone Cancer by Peter Hutch
Bone cancer that originates in the bone — primary bone cancer — is rare. Fewer than 2,500 Americans are diagnosed with this type of cancer each year. The condition affects more children than adults. Bone cancer is a malignant (cancerous) tumor of the bone that destroys normal bone tissue (1). Not all bone tumors are malignant. In fact, benign (noncancerous) bone tumors are more common than malignant ones. Both malignant and benign bone tumors may grow and compress healthy bone tissue, but benign tumors do not spread, do not destroy bone tissue, and are rarely a threat to life.
Most of the time when someone with cancer is told they have bone cancer, the doctor is talking about a cancer that spread there from somewhere else. This is called metastatic cancer and can be seen in people with advanced breast cancer, prostate cancer, lung cancer as well as many others. When these cancers in the bone are examined under a microscope they resemble the tissue they came from. If someone has lung cancer spread to bone, the cells of the cancer look and act like lung cancer cells, not bone cancer cells, even after they have spread from the lungs to the bones. They are treated with the same kind of treatment (chemotherapy drugs, for example) that is used for lung cancer.
Malignant tumors that begin in bone tissue are called primary bone cancer. Cancer that metastasizes (spreads) to the bones from other parts of the body, such as the breast, lung, or prostate, is called metastatic cancer, and is named for the organ or tissue in which it began. Primary bone cancer is far less common than cancer that spreads to the bones.
Bone cancer: Primary bone cancer is cancer that forms in cells of the bone. Some types of primary bone cancer are osteosarcoma, Ewing's sarcoma, malignant fibrous histiocytoma, and chondrosarcoma. Secondary bone cancer is cancer that spreads to the bone from another part of the body (such as the prostate, breast, or lung). The most common types of primary bone tumour are osteosarcoma and Ewing's sarcoma, both of which are most frequently diagnosed in children and young adults.
The first symptom of bone cancer is usually pain or tenderness near the cancer. Bone pain is caused by stretching of the periosteum (thick membrane that covers bone) by the cancer, or by stimulation of nerves within the bone. Bone pain may be hard to differentiate from ordinary low back pain or arthritis. Usually the pain due to bone metastasis is fairly constant, even at night. It can be worse in different positions, such as standing up, which may compress the cancer in a weight bearing bone. If pain lasts for more than a week or two, doesn't seem to be going away, and is unlike other pain that may have been experienced, it should be evaluated by a physician.
Bone cancer is caused by a problem with the cells that make bone. More than 2,000 people are diagnosed in the United States each year with a bone tumor. Bone tumors occur most commonly in children and adolescents and are less common in older adults. Cancer involving the bone in older adults is most commonly the result of metastatic spread from another tumor.
The most common symptom of bone cancer is pain. Other symptoms may vary depending on the location and size of the cancer. Surgery is often the main treatment for bone cancer. Other treatments may include amputation, chemotherapy and radiation.
Read about Home Remedies, Natural Home Remedy . Also read about Body Building Tips Guide Body Building Supplements and Hair Loss Treatment
Article Source: Free Articles ArticleSnatch Article Directory
Bone cancer that originates in the bone — primary bone cancer — is rare. Fewer than 2,500 Americans are diagnosed with this type of cancer each year. The condition affects more children than adults. Bone cancer is a malignant (cancerous) tumor of the bone that destroys normal bone tissue (1). Not all bone tumors are malignant. In fact, benign (noncancerous) bone tumors are more common than malignant ones. Both malignant and benign bone tumors may grow and compress healthy bone tissue, but benign tumors do not spread, do not destroy bone tissue, and are rarely a threat to life.
Most of the time when someone with cancer is told they have bone cancer, the doctor is talking about a cancer that spread there from somewhere else. This is called metastatic cancer and can be seen in people with advanced breast cancer, prostate cancer, lung cancer as well as many others. When these cancers in the bone are examined under a microscope they resemble the tissue they came from. If someone has lung cancer spread to bone, the cells of the cancer look and act like lung cancer cells, not bone cancer cells, even after they have spread from the lungs to the bones. They are treated with the same kind of treatment (chemotherapy drugs, for example) that is used for lung cancer.
Malignant tumors that begin in bone tissue are called primary bone cancer. Cancer that metastasizes (spreads) to the bones from other parts of the body, such as the breast, lung, or prostate, is called metastatic cancer, and is named for the organ or tissue in which it began. Primary bone cancer is far less common than cancer that spreads to the bones.
Bone cancer: Primary bone cancer is cancer that forms in cells of the bone. Some types of primary bone cancer are osteosarcoma, Ewing's sarcoma, malignant fibrous histiocytoma, and chondrosarcoma. Secondary bone cancer is cancer that spreads to the bone from another part of the body (such as the prostate, breast, or lung). The most common types of primary bone tumour are osteosarcoma and Ewing's sarcoma, both of which are most frequently diagnosed in children and young adults.
The first symptom of bone cancer is usually pain or tenderness near the cancer. Bone pain is caused by stretching of the periosteum (thick membrane that covers bone) by the cancer, or by stimulation of nerves within the bone. Bone pain may be hard to differentiate from ordinary low back pain or arthritis. Usually the pain due to bone metastasis is fairly constant, even at night. It can be worse in different positions, such as standing up, which may compress the cancer in a weight bearing bone. If pain lasts for more than a week or two, doesn't seem to be going away, and is unlike other pain that may have been experienced, it should be evaluated by a physician.
Bone cancer is caused by a problem with the cells that make bone. More than 2,000 people are diagnosed in the United States each year with a bone tumor. Bone tumors occur most commonly in children and adolescents and are less common in older adults. Cancer involving the bone in older adults is most commonly the result of metastatic spread from another tumor.
The most common symptom of bone cancer is pain. Other symptoms may vary depending on the location and size of the cancer. Surgery is often the main treatment for bone cancer. Other treatments may include amputation, chemotherapy and radiation.
Read about Home Remedies, Natural Home Remedy . Also read about Body Building Tips Guide Body Building Supplements and Hair Loss Treatment
Article Source: Free Articles ArticleSnatch Article Directory
Subscribe to:
Posts (Atom)
